uploads/2019/01/green-1648353_1280-4.jpg

OrganiGram Rose 18% after Its First-Quarter Earnings

By

Updated

OrganiGram reports earnings

On January 28, OrganiGram (OGRMF) reported its first-quarter earnings for the quarter ending November 30. The earnings were received well and exceeded investors’ expectations. The stock rose as much as 18% to $5.31 compared to the closing the previous market day. Let’s look at the key results from OrganiGram’s earnings.

Article continues below advertisement

Results

The net revenues were $12.4 million Canadian dollars—excluding excise taxes, which grew nearly 500% year-over-year from 2.4 million Canadian dollars in the first quarter of 2018. Sequentially, the company’s top line grew ~352% from 3.2 million Canadian dollars.

Why did the revenues grow?

The legalization of recreational cannabis in Canada boosted the company’s revenues from adult-use cannabis. When peers (HMMJ) including Canopy Growth (WEED) (CGC), Aurora Cannabis (ACB), and Tilray (TLRY) report their earnings, we could see a similar increase in sales due to Canada’s recreational cannabis legalization.

In a press release, OrganiGram stated that “the Company not only experienced its highest sales quarter of all time, but it also surpassed in a single quarter what it has historically done in an entire year of sales on the medical side.” The statement accurately sums up why the cannabis industry has garnered investors’ attention.

Advertisement

More From Market Realist